Scott Arthur Tomlins
#153,955
Most Influential Person Now
Scott Arthur Tomlins's AcademicInfluence.com Rankings
Scott Arthur Tomlinslaw Degrees
Law
#2701
World Rank
#3354
Historical Rank
Common Law
#134
World Rank
#144
Historical Rank
International Law
#707
World Rank
#870
Historical Rank
Scott Arthur Tomlinsengineering Degrees
Engineering
#6345
World Rank
#7664
Historical Rank
Biomedical Engineering
#558
World Rank
#568
Historical Rank
Download Badge
Law Engineering
Scott Arthur Tomlins's Degrees
- PhD Biomedical Engineering University of California, San Francisco
- Bachelors Biomedical Engineering University of California, San Francisco
Why Is Scott Arthur Tomlins Influential?
(Suggest an Edit or Addition)Scott Arthur Tomlins's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. (2006) (2694)
- Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (2458)
- The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer (2012) (2144)
- The Molecular Taxonomy of Primary Prostate Cancer (2015) (2116)
- EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells (2003) (1605)
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer (2005) (1539)
- Divergent clonal evolution of castration resistant neuroendocrine prostate cancer (2016) (1032)
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer (2013) (915)
- Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer (2007) (854)
- An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. (2010) (800)
- Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. (2005) (784)
- Integrative molecular concept modeling of prostate cancer progression (2007) (725)
- Role of the TMPRSS2-ERG gene fusion in prostate cancer. (2008) (679)
- Genomic correlates of clinical outcome in advanced prostate cancer (2019) (647)
- Identification of targetable FGFR gene fusions in diverse cancers. (2013) (606)
- Integrative Clinical Genomics of Metastatic Cancer (2017) (574)
- Recurrent gene fusions in prostate cancer (2008) (572)
- Repression of E-cadherin by the polycomb group protein EZH2 in cancer (2008) (566)
- TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. (2006) (539)
- TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. (2006) (488)
- Probabilistic model of the human protein-protein interaction network (2005) (459)
- Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma (2010) (442)
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (2018) (398)
- Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. (2011) (398)
- Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer (2009) (395)
- Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). (2005) (389)
- ETS gene fusions in prostate cancer: from discovery to daily clinical practice. (2009) (383)
- Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (383)
- Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA (2011) (364)
- Antibody-based detection of ERG rearrangement-positive prostate cancer. (2010) (358)
- A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. (2007) (346)
- The role of SPINK1 in ETS rearrangement-negative prostate cancers. (2008) (327)
- A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. (2008) (323)
- Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer (2007) (319)
- Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. (2016) (318)
- Prostate cancer (2016) (288)
- Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. (2008) (283)
- Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. (2006) (259)
- The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. (2015) (248)
- PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. (2012) (244)
- Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands (2015) (234)
- The Potential of MicroRNAs as Prostate Cancer Biomarkers. (2016) (232)
- Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. (2007) (229)
- Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States (2009) (229)
- Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression (2009) (224)
- Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. (2007) (220)
- Coordinated regulation of polycomb group complexes through microRNAs in cancer. (2011) (217)
- Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo (2006) (215)
- Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. (2013) (211)
- Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy (2017) (193)
- Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. (2017) (191)
- FIZZ1 stimulation of myofibroblast differentiation. (2004) (187)
- Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. (2008) (173)
- Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. (2016) (163)
- Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. (2017) (160)
- Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer (2004) (159)
- A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. (2008) (159)
- Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. (2017) (155)
- The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy (2007) (151)
- Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. (2007) (148)
- Therapeutic Targeting of SPINK1-Positive Prostate Cancer (2011) (146)
- AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist (2009) (144)
- Evidence for a functional role of the second C5a receptor C5L2 (2005) (143)
- Integrative analysis of genomic aberrations associated with prostate cancer progression. (2007) (139)
- DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. (2015) (137)
- Autopsy findings in eight patients with fatal H1N1 influenza. (2010) (136)
- Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. (2015) (135)
- Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. (2007) (134)
- Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors12 (2015) (126)
- Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. (2012) (126)
- CHARACTERIZATION OF TMPRSS2-ETS GENE ABERRATIONS IN ANDROGEN INDEPENDENT METASTATIC PROSTATE CANCER (2008) (120)
- Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer (2018) (118)
- Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors (2015) (114)
- Association Between Combined TMPRSS2: ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer (2017) (111)
- Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data. (2015) (109)
- Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty (2005) (106)
- Managing Nonmetastatic Castration-resistant Prostate Cancer. (2019) (106)
- Cellular and Genetic Causes of Idiopathic Hyperaldosteronism (2018) (106)
- Histopathological Classification of Cross-Sectional Image–Negative Hyperaldosteronism (2016) (101)
- Genetic Characteristics of Aldosterone-Producing Adenomas in Blacks (2019) (101)
- Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. (2016) (100)
- Next-Generation Sequencing of Tubal Intraepithelial Carcinomas. (2015) (100)
- CD24 is an effector of HIF-1-driven primary tumor growth and metastasis. (2012) (100)
- Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma (2016) (98)
- DNA methylation landscapes in advanced prostate cancer (2020) (98)
- Targeted Molecular Characterization of Aldosterone-Producing Adenomas in White Americans (2018) (97)
- Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. (2008) (95)
- Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma (2009) (94)
- The tumor suppressor gene rap1GAP is silenced by mir-101-mediated EZH2 overexpression in invasive squamous cell carcinoma (2011) (94)
- Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. (2011) (91)
- Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. (2016) (89)
- Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy. (2015) (89)
- ETS rearrangements and prostate cancer initiation (2009) (87)
- Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase–deficient Renal Cell Carcinoma (2018) (83)
- Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. (2012) (83)
- Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation (2016) (77)
- Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity (2007) (77)
- Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. (2012) (77)
- Aldosterone-Producing Cell Clusters Frequently Harbor Somatic Mutations and Accumulate With Age in Normal Adrenals (2017) (77)
- The prostate cancer genome: perspectives and potential. (2014) (76)
- Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms. (2018) (73)
- A distinctive, low‐grade oncocytic fumarate hydratase‐deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase‐deficient renal cell carcinoma (2017) (69)
- Molecular Heterogeneity in Aldosterone-Producing Adenomas. (2016) (69)
- Elevated α-Methylacyl-CoA Racemase Enzymatic Activity in Prostate Cancer (2004) (67)
- Activating ESR 1 mutations in hormone-resistant metastatic breast cancer (2013) (66)
- Role of transcriptional corepressor CtBP1 in prostate cancer progression. (2012) (64)
- Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays (2018) (64)
- Intra-tumor Genetic Heterogeneity in Rectal Cancer (2015) (63)
- Integrative biology of prostate cancer progression. (2006) (63)
- Phenotypic diversity of circulating tumour cells in patients with metastatic castration‐resistant prostate cancer (2017) (63)
- Transcriptomic heterogeneity in multifocal prostate cancer. (2018) (62)
- Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management (2019) (61)
- Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy. (2017) (60)
- Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies (2016) (59)
- Association of Tumor Infiltrating T-cell Density with Molecular Subtype, Racial Ancestry and Clinical Outcomes in Prostate Cancer (2018) (57)
- ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms. (2015) (57)
- Translational and clinical implications of the genetic landscape of prostate cancer (2016) (55)
- Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. (2018) (55)
- Molecular markers of prostate cancer. (2006) (54)
- Comprehensive Genomic Profiling of Orbital and Ocular Adnexal Lymphomas Identifies Frequent Alterations in MYD88 and Chromatin Modifiers: New Routes to Targeted Therapies (2016) (54)
- Independent surgical validation of the new prostate cancer grade‐grouping system (2016) (54)
- Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition (2006) (53)
- TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. (2011) (52)
- Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. (2004) (52)
- Whole transcriptome amplification for gene expression profiling and development of molecular archives. (2006) (50)
- The CARMA3-Bcl10-MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer. (2018) (49)
- Erratum: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (Cell (2018) 174(3) (758–769.e9), (S0092867418308420) (10.1016/j.cell.2018.06.039)) (2018) (48)
- Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma (2013) (47)
- Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma (2015) (46)
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (2018) (44)
- The DNA methylation landscape of advanced prostate cancer (2020) (44)
- Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas (2018) (44)
- Urine TMPRSS 2 : ERG Plus PCA 3 for Individualized Prostate Cancer Risk Assessment (2016) (44)
- Evaluation of Tissue PCA3 Expression in Prostate Cancer by RNA in situ Hybridization - A Correlative Study with Urine PCA3 and TMPRSS2-ERG (2013) (43)
- Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. (2016) (43)
- A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. (2020) (43)
- Somatic CACNA1H Mutation As a Cause of Aldosterone-Producing Adenoma (2020) (43)
- The discovery and application of gene fusions in prostate cancer (2008) (42)
- Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up (2016) (42)
- HOXB13 G84E–related Familial Prostate Cancers: A Clinical, Histologic, and Molecular Survey (2014) (40)
- Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy (2017) (40)
- Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer (2018) (39)
- The Molecular Evolution of Castration-resistant Prostate Cancer. (2016) (37)
- HRAS mutations are frequent in inverted urothelial neoplasms. (2014) (37)
- Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer. (2009) (36)
- Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. (2004) (35)
- Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration‐resistant prostate cancer (2014) (35)
- Assessment of long‐term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy (2015) (34)
- Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations. (2016) (33)
- The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development (2020) (33)
- The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer (2016) (32)
- Aldosterone-Producing Cell Clusters in Normal and Pathological States (2017) (32)
- Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature (2018) (32)
- Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium (2017) (31)
- Urine PCA3 and TMPRSS2:ERG using cancer-specific markers to detect cancer. (2014) (31)
- The role of the histone H3 variant CENPA in prostate cancer (2020) (31)
- Integrative molecular profiling of routine clinical prostate cancer specimens. (2015) (30)
- Double adrenocortical adenomas harboring independent KCNJ5 and PRKACA somatic mutations. (2016) (30)
- Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer (2020) (30)
- Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications (2017) (30)
- Fibulin-3 promotes muscle-invasive bladder cancer (2017) (30)
- Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive Biomarkers (2021) (29)
- Clonal Evaluation of Prostate Cancer Foci in Biopsies with Discontinuous Tumor Involvement by Dual ERG/SPINK1 Immunohistochemistry (2015) (29)
- Novel RNA Hybridization Method for the In Situ Detection of ETV1, ETV4, and ETV5 Gene Fusions in Prostate Cancer (2014) (29)
- TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer. (2019) (29)
- Cross-talk between the calcium-sensing receptor and the epidermal growth factor receptor in Rat-1 fibroblasts. (2005) (28)
- Evidence of recurrent gene fusions in common epithelial tumors. (2006) (27)
- Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors. (2013) (27)
- Invasive squamous cell carcinomas and precursor lesions on UV-exposed epithelia demonstrate concordant genomic complexity in driver genes (2020) (26)
- Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low‐risk patient as defined by targeted sequencing (2016) (26)
- Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile (2019) (26)
- Histological characterization of aldosterone-producing adrenocortical adenomas with different somatic mutations. (2019) (25)
- Minimally Invasive Inguinal Lymphadenectomy in the Management of Penile Carcinoma. (2017) (25)
- Prevalence of somatic mutations in aldosterone-producing adenomas in Japanese. (2020) (24)
- Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer (2014) (24)
- Molecular Profiling of Multiple Primary Merkel Cell Carcinoma to Distinguish Genetically Distinct Tumors From Clonally Related Metastases (2017) (24)
- Characterization of TMPRSS 2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer (2008) (23)
- Prostate Cancer SubtyPINg BiomarKers and Outcome: Is Clarity EmERGing? (2014) (22)
- Comprehensive serial molecular profiling of an “N of 1” exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment (2015) (22)
- Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations. (2014) (22)
- Circulating Tumor Cell–Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (2019) (21)
- Development and Validation of a Deep-Learning Model to Assist with Renal Cell Carcinoma Histopathologic Interpretation. (2020) (21)
- AGTR1 as a therapeutic target in ER-positive and ERBB-negative breast cancer cases (2009) (21)
- Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer (2016) (21)
- Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer12 (2016) (20)
- At the intersection of primary pulmonary myxoid sarcoma and pulmonary angiomatoid fibrous histiocytoma: observations from three new cases (2014) (20)
- Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer. (2019) (20)
- Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer (2018) (19)
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factors in Prostate Cancer (2006) (18)
- A Genomic Survey of Sarcomas on Sun-Exposed Skin Reveals Distinctive Candidate Drivers and Potentially Targetable Mutations. (2020) (18)
- Quantifying Gleason scores with photoacoustic spectral analysis: feasibility study with human tissues. (2015) (18)
- Consequence of the tumor-associated conversion to cyclin D1b (2015) (18)
- Abiraterone + prednisone (Abi) +/- veliparib (Vel) for patients (pts) with metastatic castration-resistant prostate cancer (CRPC): NCI 9012 updated clinical and genomics data. (2017) (18)
- Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. (2022) (18)
- Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. (2019) (18)
- Genetic and Histopathologic Intertumor Heterogeneity in Primary Aldosteronism. (2017) (18)
- Informing a risk prediction model for binary outcomes with external coefficient information (2018) (17)
- Integrating Biomedical Knowledge to Model Pathways of Prostate Cancer Progression (2007) (17)
- Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma. (2018) (17)
- Understanding the relationship between tumor size, gland size, and disease aggressiveness in men with prostate cancer. (2014) (16)
- Interstitial assessment of aggressive prostate cancer by physio‐chemical photoacoustics: An ex vivo study with intact human prostates (2018) (16)
- Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer (2019) (16)
- TP53 Mutations and CDKN2A Mutations/Deletions are Highly Recurrent Molecular Alterations in the Malignant Progression of Sinonasal Papillomas (2020) (16)
- Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer. (2019) (16)
- Diffuse large B-cell lymphoma of the prostate. (2014) (15)
- Use of the MyProstateScore (MPS) Test to Rule Out Clinically-Significant Cancer: Validation of a Straightforward Clinical Testing Approach. (2020) (15)
- Optimization of Complex Cancer Morphology Detection Using the SIVQ Pattern Recognition Algorithm (2011) (15)
- Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. (2016) (15)
- DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway (2019) (15)
- Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer (2018) (15)
- Integrative Clinical Genomics of Advanced Prostate Cancer Graphical (2015) (14)
- Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. (2017) (14)
- Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts. (2019) (14)
- Histotripsy of the Prostate in a Canine Model: Characterization of Post-Therapy Inflammation and Fibrosis. (2015) (14)
- CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer (2020) (14)
- Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas (2019) (13)
- Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series (2014) (13)
- Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples (2021) (12)
- Role of dutasteride in pre‐clinical ETS fusion‐positive prostate cancer models (2012) (12)
- CD38 in Advanced Prostate Cancers (2021) (12)
- Multiclonality and Marked Branched Evolution of Low-Grade Endometrioid Endometrial Carcinoma (2019) (12)
- Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. (2007) (12)
- SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy (2019) (11)
- Of mice and men: cancer gene discovery using comparative oncogenomics. (2006) (11)
- Reprint of: The prostate cancer genome: Perspectives and potential. (2015) (11)
- Molecular Biomarkers in the Clinical Management of Prostate Cancer. (2018) (10)
- Abstract 4681: Inhibition of poly (ADP-ribose) polymerase-1 (PARP-1) as a strategy for targeted therapy in Ewing's sarcoma (2012) (10)
- Prostate cancer characterization by optical contrast enhanced photoacoustics (2016) (10)
- Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer (2017) (9)
- Targeted RNAseq of Formalin-Fixed Paraffin-Embedded Tissue to Differentiate Among Benign and Malignant Adrenal Cortical Tumors (2020) (8)
- Determination of Optimum Formalin Fixation Duration for Prostate Needle Biopsies for Immunohistochemistry and Quantum Dot FISH Analysis (2015) (8)
- Clinical application of comprehensive next generation sequencing in the management of metastatic cancer in adults. (2017) (8)
- Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers (2019) (8)
- Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. (2020) (8)
- Integrative molecular profiling of routine clinical prostate cancer specimens. (2015) (8)
- Anatomical patterns of recurrence following biochemical relapse after post‐prostatectomy salvage radiation therapy: a multi‐institutional study (2017) (8)
- Targeted next-generation sequencing of CIC-DUX4 soft tissue sarcomas demonstrates low mutational burden and recurrent chromosome 1p loss. (2016) (8)
- A randomized phase II trial of abiraterone, olaparib or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair defects. (2017) (8)
- The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment (2016) (8)
- Immediate early inflammatory gene responses of human umbilical vein endothelial cells to hemorrhagic venom (2011) (7)
- Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology (2015) (7)
- Noninvasive Detection of TMPRSS 2 : ERG Fusion Transcripts in the Urine of Men with Prostate Cancer 1 (2014) (7)
- A five‐CpG DNA methylation score to predict metastatic‐lethal outcomes in men treated with radical prostatectomy for localized prostate cancer (2018) (7)
- Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression (2015) (7)
- Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies (2022) (7)
- Enhancing the anti-tumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. (2004) (6)
- A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer (2021) (6)
- Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series. (2014) (5)
- Somatic mutations in adrenocortical carcinoma with primary aldosteronism or hyperreninemic hyperaldosteronism (2019) (5)
- CK- and small nuclear size circulating tumor cell (CTCs) phenotypes in metastatic castration-resistant prostate cancer (mCRPC). (2014) (5)
- Histopathological classification of cross-sectional image negative hyperaldosteronism. (2016) (5)
- The Genomic Landscape of Prostate Cancer Brain Metastases (2020) (5)
- Alterations in homologous recombination repair genes in prostate cancer brain metastases (2022) (5)
- Cotargeting AR signaling and cell cycle: A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone sensitive prostate cancer (mHSPC). (2018) (5)
- Photoacoustic spectral analysis at ultraviolet wavelengths for characterizing the Gleason grades of prostate cancer. (2020) (5)
- Relevance of pRB Loss in Human Malignancies (2021) (5)
- Development and Validation of StrataNGS, a Multiplex PCR, Semiconductor Sequencing-Based Comprehensive Genomic Profiling Test. (2021) (5)
- Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections (2018) (4)
- Clinical outcomes and markers of treatment response in a randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-intact metastatic hormone-sensitive prostate cancer (mHSPC). (2020) (4)
- Concordance of ETS fusion status of matched metastatic castration-resistant prostate cancer and primary prostate cancer: Data from NCI 9012, a randomized ETS fusion-stratified phase II trial. (2014) (4)
- Molecular Clues Assist in the Cancer Clinic (2013) (4)
- to stimulate chemokine production and neutrophil recruitment in vivo (2006) (4)
- Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer (2022) (3)
- Discovery and Characterization of Recurrent Gene Fusions in Prostate Cancer. (2007) (3)
- Identification and Validation of Intrinsic Subtypes of Prostate Cancer. (2016) (3)
- Integrative molecular profiling challenges robustness of prognostic signature scores in multifocal prostate cancer. (2018) (3)
- Advances in Biomarkers for Prostate Diseases (2006) (3)
- Urinary MyProstateScore (MPS) to rule out clinically-significant cancer in men with equivocal (PI-RADS 3) multiparametric MRI: addressing an unmet clinical need. (2021) (3)
- Next generation sequencing identifies recurrent copy number variations in invasive breast carcinomas from Ghana (2020) (3)
- Targeted DNA and RNA sequencing of paired urothelial and squamous bladder cancers to reveal discordant genomic and transcriptomic events and unique therapeutic opportunities. (2017) (2)
- Twenty-first century pathology sign-out. (2012) (2)
- Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy (2021) (2)
- Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study (2021) (2)
- Reply to Carsten Stephan, Henning Cammann, and Klaus Jung's Letter to the Editor re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039. (2015) (2)
- MICHIGAN PROSTATE SCORE (MIPS): AN ANALYSIS OF A NOVEL URINARY BIOMARKER PANEL FOR THE PREDICTION OF PROSTATE CANCER AND ITS IMPACT ON BIOPSY RATES: PD07‐03 (2017) (2)
- Novel urine markers for diagnosing and monitoring non-indolent prostate cancer. (2015) (2)
- Progression of low- to high-grade prostate cancer: Molecular profiling of tissue obtained by serial targeted biopsy. (2015) (2)
- Somatic mutations in adrenocortical carcinoma with hyperaldosteronism. (2018) (2)
- Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer. (2021) (2)
- Recurrent gene fusions in prostate cancer: ETV1 class of fusions (2007) (2)
- Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit (2023) (2)
- PD43-12 EFFECT OF TREATMENT DELAY ON LONG-TERM OUTCOMES IN MEN UNDERGOING RADICAL PROSTATECTOMY FOR PROSTATE CANCER. (2015) (2)
- 2121 URINE MEASUREMENT OF TMPRSS2:ERG FOR THE EARLY DETECTION OF SIGNIFICANT PROSTATE CANCER (2010) (2)
- Focal radiation for oligometastatic castration-resistant prostate cancer (FORCE): A phase II randomized trial. (2019) (2)
- Tomlins et al. reply (2009) (2)
- Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection (2021) (2)
- Role of Transcriptional Corepressor CtBP1 in Prostate (2012) (2)
- In vivo biopsy by photoacousticUS based tissue characterization (2015) (2)
- Photoacoustic biopsy: a feasibility study (2015) (2)
- Androgen regulation of prostate cancer gene fusions (2009) (2)
- 1436: Comprehensive Assessment of TMPRSS2 and ETS Family Gene Aberrations in Clinically Localized Prostate Cancer (2007) (2)
- 430 Analysis of 2,700 Cancer Exomes to Identify Novel Cancer Drivers and Therapeutic Opportunities (2012) (2)
- TARGETED NEXT GENERATION SEQUENCING TO CHARACTERIZE MAGNETIC RESONANCE IMAGING VISIBLE AND INVISIBLE PROSTATE CANCER: BIOLOGICAL INSIGHTS AND THERAPEUTIC IMPLICATIONS: PD33‐05 (2017) (1)
- Identification of gene expression determinants of radiosensitivity in bladder cancer (BCa) cell lines. (2018) (1)
- Abstract 2815: Urine TMPRSS2:ERG for prostate cancer risk stratification in men with elevated serum PSA (2011) (1)
- 187 Targeted genomic profiling of penile squamous cell carcinoma using the Oncomine cancer research panel (2014) (1)
- Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen. (2021) (1)
- MP26-12 USE OF THE MYPROSTATESCORE (MPS) TEST FOR RISK STRATIFICATION IN MEN WITH A PREVIOUS NEGATIVE BIOPSY: INITIAL VALIDATION OF A STRAIGHTFORWARD TESTING APPROACH (2021) (1)
- No-cost next generation sequencing of advanced cancer patients within the Strata Precision Oncology Network supports clinical trial enrollment. (2019) (1)
- [Molecular pathology of urogenital tumors : Recommendations from the 2019 International Society of Urological Pathology (ISUP) Consensus Conference]. (2021) (1)
- The Oncomine Cancer Research Panel, a scalable next-generation sequencing system for relevant somatic variant assessment in solid tumors. (2015) (1)
- MP62-17 ENZALUTAMIDE IN PATIENTS WITH LOCALIZED PROSTATE CANCER UNDERGOING ACTIVE SURVEILLANCE: ENACT (2021) (1)
- Molecular Pathology of Prostate Cancer (2017) (1)
- ERG EXPRESSION VARIES IN DIFFERENT ISOFORMS OF TMPRSS2:ERG GENE FUSION IN PROSTATE CANCER (2008) (1)
- Predictors of Rapid Treatment Failure After Postoperative Radiation Therapy: A Multicenter Study (2016) (1)
- SAT-352 Comprehensive Genetic Analysis of Cortisol-Producing Adenomas (2019) (1)
- Abstract 899: TMPRSS2:ERG urine test identifies Gleason score upgrading and significant prostate cancer (2011) (1)
- An observational study profiling biospecimens from 10,000 metastatic prostate cancer (mPCa) patients to screen for molecular alterations. (2018) (1)
- TMPRSS2-ERG FUSION PROSTATE CANCER PREVALENCE, ASSOCIATION WITH PSA DENSITY, AND HISTOLOGIC FEATURES IN A MULTI-CENTER U.S. COHORT OF MEN UNDERGOING PROSTATE BIOPSY (2008) (1)
- Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer (2013) (1)
- MP1-14 DEFINING ADVERSE PATHOLOGY FOR LOWER RISK MEN UNDERGOING RADICAL PROSTATECTOMY (2015) (1)
- MyProstateScore in men considering repeat biopsy: validation of a simple testing approach. (2022) (1)
- Prostate Cancer Molecular Prognosis (2018) (1)
- A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer. (2015) (1)
- Impact of the MyProstateScore (MPS) test on the clinical decision to undergo prostate biopsy: results from a contemporary academic practice (2020) (1)
- Molecular Characterization of a Rare Case of Bilateral Vitreoretinal T Cell Lymphoma through Vitreous Liquid Biopsy (2021) (1)
- Gene Fusions in Prostate Cancer (2015) (1)
- PI-08 COMBINING URINE PCA3 AND TMPRSS2: ERG TESTS TO REFINE PROSTATE CANCER DETECTION – VALIDATION STUDY AND HEALTH ECONOMIC ANALYSIS (2015) (1)
- Comprehensive molecular profiling of pretreatment metastatic castration resistant prostate cancer (CRPC): Secondary data from NCI 9012, a randomized ETS fusion-stratified phase II trial. (2014) (1)
- PCR-based comprehensive genomic profiling (PCR-CGP): Feasibility from >20,000 tumor tissue specimens (TTS) and predicted impact on actionable biomarker identification versus hybrid capture (H)-CGP and plasma (P)-CGP. (2020) (1)
- A 24-Gene Predictor of Response to Postoperative Radiation Therapy in Prostate Cancer. (2016) (1)
- Evaluation of Gleason scores by photoacoustic spectral analysis (2015) (1)
- Identification of gene copy number and whole-genome methylation changes associated with lethal metastatic castration-resistant prostate cancer (CRPC). (2011) (1)
- Impact of the MyProstateScore (MPS) test on the clinical decision to undergo prostate biopsy: results from a contemporary academic practice. (2020) (1)
- Abstract 953: Mechanistic rationale for inhibition of Poly(ADP-Ribose) Polymerase in ETS gene fusion positive prostate cancer (2011) (1)
- Next generation sequencing of primary prostate cancer tumors to reveal potentially actionable opportunities for clinical management: The UNC experience. (2019) (1)
- Molecular Pathology of Genitourinary Cancers: Translating the Cancer Genome to the Clinic (2015) (1)
- Abstract 4348: Validation of an integrative pan-solid tumor predictor of pembrolizumab monotherapy benefit (2023) (0)
- Abstract 4216: Novel RNAIn situhybridization method for the detection of ETV1, ETV4 and ETV5 rearrangements in prostate cancer. (2013) (0)
- MP02-07 NOVEL URINE MARKERS FOR DIAGNOSING AND MONITORING NON-INDOLENT PROSTATE CANCER (2016) (0)
- Validation of a 22-gene Epithelial-Mesenchymal Transition (EMT) prognostic signature in clear cell renal cell carcinoma (2022) (0)
- DEVELOPMENT OF A MULTIPLEX QUANTITATIVE PCR SIGNATURE TO PREDICT POOR OUTCOME IN BLADDER CANCER (2008) (0)
- Indentification of a CTC-based gene expression signature predicting resistance to abiraterone and enzalutamide in mCRPC. (2017) (0)
- CLINICOPATHOLOGIC CHARACTERISTICS OF PATIENTS UNDERGOING PROSTATE CORE BIOPSY WITH HIGH‐RISK (PI‐RADS 5) LESIONS BY MULTIPARAMETRIC PROSTATE MAGNETIC RESONANCE IMAGING.: MP38‐18 (2017) (0)
- Antibody-Based Detection of ERG Rearrangement-Positive (2010) (0)
- MP13-08 RADIOGENOMIC DISSECTION OF MULTIFOCAL PROSTATE CANCER (2019) (0)
- – Prostate Cancer – Editor ’ s Choice Managing Nonmetastatic Castration-resistant Prostate Cancer (2019) (0)
- Abstract LB-262: Estimation of tumor content from exome sequencing data (2011) (0)
- PP 21 Gene expression module biomarkers to stratify multiple clinical and therapeutic endpoints for universal breast cancer companion diagnostic (2011) (0)
- Tomlins Men with Elevated Serum PSA Fusion Transcript Stratifies Prostate Cancer Risk in TMPRSS 2 : ERG Urine (2011) (0)
- MOLECULAR PROFILING OF MULTI‐FOCAL PROSTATE CANCER AND CONCOMITANT LYMPH NODE METASTASIS: IMPLICATIONS FOR TISSUE‐BASED PROGNOSTIC BIOMARKERS: PD07‐12 (2017) (0)
- Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling (2017) (0)
- Percent genome alteration and outcomes after radical prostatectomy in African American men. (2019) (0)
- Abstract IA06: Co-Targeting cell cycle and androgen signaling to personalize therapy for hormone dependent prostate cancer (2016) (0)
- Abstract 611: Assessment of tumor mutation burden and microsatellite instability by single-cell circulating tumor cell genomic profiling (2022) (0)
- Abstract 2564: Identification of a novel SPOP missense mutation from targeted next-generation sequencing of men with chromosome 17-q linkage. (2013) (0)
- Dissection of primary prostate cancer to determine the clonal origin of synchronous lymph node metastasis. (2020) (0)
- Abstract 3664: Breast cancer companion diagnostic platform based on objectively defined tumor co-expression patterns stratifies multiple clinical and therapeutic endpoints comparison to existing molecular subtyping definitions (2012) (0)
- PD08-12 PROGNOSTIC VALUE OF PERCENT GLEASON GRADE 4 IN PROSTATE BIOPSY SPECIMENS AFTER RADICAL PROSTATECTOMY (2016) (0)
- Radiogenomic characterization of multifocal prostate cancer (2019) (0)
- Abstract 3143: Monitoring circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) genomic alterations in ER positive (POS)/HER2 negative (NEG) advanced breast cancer during endocrine therapy: correlative study of AZD9496 oral SERD phase I trial (2021) (0)
- MP28-10 AUTOMATED DIGITAL ANALYSIS OF RENAL CORE BIOPSY SPECIMENS USING A DEEP-LEARNING ARTIFICIAL INTELLIGENCE NETWORK (2018) (0)
- Abstract 2780: Xenografts of human prostate cancer - a genetic profile analysis. (2013) (0)
- Evaluating the clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer (PCa). (2019) (0)
- Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in (2015) (0)
- Abstract 2155: The origins and functional consequences of ETS gene fusions in prostate cancer (2011) (0)
- Clonal Evaluation of Prostate Cancer by ERG/SPINK1 Status to Improve Prognosis Prediction (2015) (0)
- Highly Recurrent IDH1 Mutations in Prostate Cancer with Psammomatous Calcification (PCWPC). (2023) (0)
- Seminar article Molecular markers of prostate cancer (2006) (0)
- Poster ViewingIntermediate Endpoints After Postprostatectomy Radiation Therapy: 5-Year Distant Metastases to Predict Overall Survival (2017) (0)
- Prognostic significance of perineural invasion in localized prostate cancer. (2015) (0)
- SPINK1 expression and outcomes postprostatectomy in race-specific cohorts. (2019) (0)
- 1345 UNDERSTANDING THE IMPACT OF THE DOMINANT NODULE AND SIZE OF THE PROSTATE ON BIOCHEMICAL RECURRENCE IN MEN WITH PROSTATE CANCER (2013) (0)
- MP6-09 MOLECULAR AND CLINICAL CHARACTERIZATION OF 1,577 PRIMARY PROSTATE CANCER TUMORS REVEALS NOVEL CLINICAL AND BIOLOGICAL INSIGHTS INTO ITS SUBTYPES (2015) (0)
- Intracellular zinc trafficking and metallothionein gene activation in HUVEC treated with Crotalus atrox venom (2017) (0)
- Expression Profiling of Prostate Cancer Progression (2007) (0)
- MP09-08 MOLECULAR DISSECTION OF GRADE PROGRESSION IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER (2020) (0)
- Molecular Pathology of Genitourinary Cancers: Translating the Cancer Genome to the Clinic (2018) (0)
- Abstract CT059: StrataPATHTM: a multicohort, non-randomized, open-label phase 2 trial to explore efficacy and safety of FDA-approved cancer therapies in novel biomarker-guided patient population (2023) (0)
- A13439 Cellular and Genetic Causes of Idiopathic Hyperaldosteronism (2018) (0)
- Feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer (mHSPC). (2017) (0)
- Solute carrier family 45 member 3 (slc45a3) and erg family gene fusions in prostate cancer (2008) (0)
- Targeting differential response using molecular guided biopsies in bone-metastatic prostate cancer. (2019) (0)
- Analysis of genomic alterations in matched circulating tumor cell DNA (CTC DNA) and plasma tumor DNA (ctDNA) in men with metastatic castration resistant prostate cancer (mCRPC). (2018) (0)
- Multicenter Independent Validation of the Zumsteg-Spratt Risk Classification System of Intermediate- and High-Risk Men Treated With Dose-Escalated Radiation Therapy Without Androgen Deprivation Therapy (2016) (0)
- MP56-12 THE ROLE OF PERINEURAL INVASION AS A PROGNOSTIC TOOL IN PROSTATE CANCER. (2015) (0)
- Validation of a 22-gene epithelial-mesenchymal transition (EMT) prognostic signature in clear cell renal cell carcinoma. (2022) (0)
- Abstract 968: Evaluation of Her2 RNA expression as a potential predictive biomarker for anti-Her2 therapy (2023) (0)
- Abstract 2171: A multivariate biomarker predicts sacituzumab govitecan response in solid tumors (2023) (0)
- Abstract A1-64: Molecular and clinical characterization of 1,577 primary prostate cancer tumors reveals novel clinical and biological insights into its subtypes (2015) (0)
- Identification of germline mutations in men with early onset prostate cancer. (2015) (0)
- PD65-10 URINARY MYPROSTATESCORE (MPS) TO RULE OUT CLINICALLY-SIGNIFICANT CANCER IN MEN WITH EQUIVOCAL (PI-RADS 3) MULTIPARAMETRIC MRI: ADDRESSING AN UNMET CLINICAL NEED (2021) (0)
- P1-07-04: Gene Expression Module Biomarkers To Stratify Multiple Clinical and Therapeutic Endpoints for Universal Breast Cancer Companion Diagnostic. (2011) (0)
- MP47-04 VALIDATION OF A 22-GENE EPITHELIAL-MESENCHYMAL TRANSITION (EMT) PROGNOSTIC SIGNATURE IN CLEAR CELL RENAL CELL CARCINOMA (2022) (0)
- SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy (2019) (0)
- Abstract LB-224: Development of a novel breast cancer segregation panel assay for multiple genetic subtyping based on gene expression modules developed from Oncomine™ (2011) (0)
- Molecular characterization of magnetic resonance imaging visible and invisible prostate cancer: Biological insights and therapeutic implications (2017) (0)
- Abstract 914: Development of a whole-urine, next-generation sequencing-based assay for early detection of aggressive prostate cancer (2019) (0)
- Anatomic Patterns of Recurrence Following Biochemical Relapse After Postprostatectomy Radiation Therapy: A Multi-institutional Study (2016) (0)
- Comprehensive molecular profiling of multifocal prostate cancer challenges the robustness of prostate cancer prognostic signatures (2018) (0)
- Abstract 1700: Serial monitoring of single-cell circulating tumor cell genomics in metastatic lobular breast cancer to identify precision and immuno-oncology biomarkers with therapeutic implications (2022) (0)
- 1703: Noninvasive Detection of TMPRSS2:Erg Fusion Transcripts in the Urine of Men with Prostate Cancer (2007) (0)
- Identification of breast cancer genomic subtypes that associate with prognosis and response to therapy in retrospective analyses. (2011) (0)
- Abstract P2-02-19: Somatic genetic profiling of circulating tumor cells (CTC) in metastatic breast cancer (MBC) patients (2016) (0)
- Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer-Reply. (2022) (0)
- Identification of clinically significant prostate cancer using a novel multiplexed urine biomarker panel (2019) (0)
- Targetable GOPC-ROS1 Gene Fusion Identified in a Case of Lethal Oral Mucosal Melanoma (2018) (0)
- Comprehensive molecular profiling of multi-focal prostate cancer and concomitant lymph node metastasis: Implications for tissue-based prognostic biomarkers. (2017) (0)
- Abstract A03: Analyses of a prostate cancer patient-derived xenografts series, a resource for translational research (2016) (0)
- MP35-19 ASSOCIATION OF URINARY PCA3 AND TMPRSS2:ERG RISK GROUPS WITH DETECTION OF PROSTATE CANCER AT REPEAT BIOPSY IN MEN WITH AN INITIAL NEGATIVE PROSTATE BIOPSY (2018) (0)
- Abstract P4-02-04: Serial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importance (2023) (0)
- Validation of imaging-based biomarkers of treatment response in patients with metastatic castrate-resistant prostate cancer treated with enzalutamide. (2016) (0)
- Prostate Cancer Tissue Diagnosis (2018) (0)
- PD53-01 DEVELOPMENT OF A WHOLE-URINE, MULTIPLEXED, NEXT GENERATION RNA-SEQUENCING ASSAY FOR AGGRESSIVE PROSTATE CANCER EARLY DETECTION (2020) (0)
- Molecular markers of grade progression in longitudinally tracked prostate cancer foci during active surveillance of low risk disease (2019) (0)
- Abstract 5874: Cdk4/6 kinase inhibitor resistance in prostate cancer (2017) (0)
- OUTLIER EXPRESSION OF SPINK1 IDENTIFIES AN AGGRESSIVE MOLECULAR SUBTYPE IN PROSTATE CANCERS WITHOUT ETS GENE FUSIONS (2008) (0)
- 430 Molecular and clinical characterization of 1,577 primary prostate cancers reveal novel clinical and biological insights into subtypes (2015) (0)
- Comprehensive Molecular Profiling of African-American Prostate Cancer to Inform on Prognosis and Disease Biology (2016) (0)
- Toll-Like Receptor Agonist Induces IFN-gþIL-17þ Polyfunctional T Cells That Mediate Rejection of Murine Tumors (2012) (0)
- Abstract 5109: The CARMA3-Bcl10-MALT1 signalosome mediates NF-κB activation and cellular invasion in AGTR1-positive breast cancer (2015) (0)
- Comprehensive genomic and transcriptomic profiling (CGTP) to predict pembrolizumab (P) benefit in patients (pts) with advanced solid tumors (STs). (2021) (0)
- Rearrangements of genes MIPOL 1-ETV1. (2008) (0)
- Comprehensive genomic profiling of 30,000 consecutive solid tumors (2020) (0)
- Identification of Putative Gene-Target Modulators of Radiosensitivity in Bladder Cancer Cell Lines (BlaCCL). (2021) (0)
- 832 Molecular profiling of prostate cancer derived from serial MRI targeted prostate biopsy in men on active surveillance (2016) (0)
- Prediction of pan-solid tumor pembrolizumab benefit by integrating tumor mutation and gene expression profiling (2022) (0)
- PD19-11 INDIVIDUALIZED PROSTATE CANCER RISK ASSESSMENT BY SERUM PSA, URINE TMPRSS2:ERG AND URINE PCA3 (2014) (0)
- Primary Aldosteronism and Genetic causes (2017) (0)
- Abstract 3929: The role of chromosome architecture in the generation of gene fusions in prostate cancer (2010) (0)
- GAS6, KLK2, AND BMP7 DETECTED IN CIRCULATING TUMOR CELLS PREDICT RESISTANCE TO CHEMOTHERAPY IN MCRPC: PD71‐07 (2017) (0)
- Resource Integrative Clinical Genomics of Advanced Prostate Cancer (2016) (0)
- Abstract 057: Cellular and Genetic Causes of Idiopathic Hyperaldosteronism (2017) (0)
- Molecular characterization to delineate the clonal evolution of primary prostate cancer with synchronous lymph node metastasis (2022) (0)
- INTEGRATIVE META-ANALYSIS OF MICROARRAY DATA TO IDENTIFY PROFILES THAT PREDICT BLADDER CANCER OUTCOMES AND PROGRESSION (2008) (0)
- ETS rearrangements and prostate cancer initiation Reply (2008) (0)
- SAT-554 Genetic Profile of Early-Onset Aldosterone-Producing Adenomas (2020) (0)
- Abstract IA08: Early detection of high-risk localized prostate cancer (2018) (0)
- Molecular characterization to delineate the clonal evolution of primary prostate cancer with synchronous lymph node metastasis. (2022) (0)
- MP79-16 INDEPENDENT SURGICAL VALIDATION OF THE 2015 PROSTATE CANCER GRADE GROUPING SYSTEM (2016) (0)
- P3.01Development and validation of a scalable next-generation sequencing system for assessing recurrent somatic alterations in solid tumors (2015) (0)
- Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer-Reply. (2022) (0)
- PD05-06 PERCENT GENOME ALTERATION PREDICTS ADVERSE ONCOLOGIC OUTCOMES AFTER RADICAL PROSTATECTOMY IN AFRICAN AMERICAN MEN: A PROFILE OF CANCER GENOMICS BY RACIAL ANCESTRY (2019) (0)
- Patient-Level DNA Damage and Repair Pathway Profiles Are Prognostic After Prostatectomy for High-Risk Prostate Cancer (2015) (0)
- Radiogenomic characterization of multifocal prostate cancer. (2019) (0)
- MP87-03 TARGETED GENE EXPRESSION PROFILING WITHIN CIRCULATING TUMOR CELLS IN MCRPC (2018) (0)
- Molecular and clinical characterization of 1,577 primary prostate cancer tumors to reveal novel clinical and biological insights into its subtypes. (2015) (0)
- Poster Session 54PROGNOSTIC BIOMARKERSMonday, 19 April, 14.00-15.30, Paris Room871 URINE MEASUREMENT OF TMPRSS2: ERG FOR THE EARLY DETECTION OF SIGNIFICANT PROSTATE CANCER (2010) (0)
- Precision medicine for vitreoretinal lymphomas: new routes to targeted therapies from liquid biopsies (2017) (0)
- Intracellular Zinc Trafficking during Crotalus atrox Venom Wound Development (2023) (0)
- Next-generation sequencing of primary prostate cancer tumors to reveal actionable opportunities for clinical management. (2019) (0)
- Transcriptomic and Mutational Analyses Identify Biological Processes Correlated with Bladder Cancer Cell Line (BlaCCL) Radiation Response (2020) (0)
- Abstract 2795: An onco-protein axis linking polycomb repressive complex 2 and polycomb repressive complex 1 through miRNAs in cancer (2011) (0)
- Abstract 3151: Genetic profiling of circulating tumor cells (CTC) in metastatic breast cancer (MBC) patients (2016) (0)
- Abstract 1447: Identification of an oncogenic germlineKRAStruncating mutation in hereditary cancers (2017) (0)
- CTC‐BASED GENE EXPRESSION FOR PREDICTING RESISTANCE TO ABIRATERONE AND ENZALUTAMIDE IN MCRPC: PD71‐06 (2017) (0)
- Abstract GMM-061: MOLECULAR CHARACTERIZATION OF MOUSE MODELS OF HIGH-GRADE SEROUS CARCINOMA ARISING IN THE OVIDUCT (2019) (0)
- Molecular and Cellular Pathobiology Common Structural and Epigenetic Changes in the Genome of Castration-Resistant Prostate Cancer (2012) (0)
- Abstract B036: Comprehensive transcriptomic profiling challenges the robustness of prostate cancer prognostic signatures to multifocality (2018) (0)
- 411: Defining Prostate Cancer Progression by Molecular Profiling of Laser Capture Micro Dissected Prostate Tissues (2006) (0)
- Molecular characterization of longitudinally tracked prostate cancer foci in men on active surveillance for low-risk disease. (2019) (0)
- 142 Next generation sequencing to determine the clonal origin of lymph node metastasis in multifocal prostate cancer: Defining the biologically dominant nodule (2016) (0)
- Abstract 692: Identifying genes that regulate bladder cancer progression and invasion (2016) (0)
- Harbingers of Aggressive Prostate Cancer: Precision Oncology Case Studies (2021) (0)
- Molecular Pro fi ling to Determine Clonality of Serial Magnetic Resonance Imaging / Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer (2016) (0)
- Abstract LB-118: A conserved checkpoint molecule signature offers novel targets for tumor specific regulatory T cell manipulation (2018) (0)
- Percent genome alteration predicts adverse oncologic outcomes after radical prostatectomy in African American men: A profile of cancer genomics by racial ancestry (2019) (0)
- Abstract 098: Aldosterone-Producing Cell Clusters in Essential Hypertension (2018) (0)
- PD64-08 IDENTIFICATION OF CLINICALLY SIGNIFICANT PROSTATE CANCER USING A NOVEL MULTIPLEXED URINE BIOMARKER PANEL (2019) (0)
- PD44-07 EFFECTIVENESS OF SERUM PSA, URINE PCA3 AND URINE TMPRSS2:ERG FUSION AS A NOVEL URINARY BIOMARKER PANEL IN CLINICAL PRACTICE (2015) (0)
- MULTI‐INSTITUTIONAL EVALUATION OF MRI AND FUSION BIOPSY IN CONFIRMATORY BIOPSY FOR ACTIVE SURVEILLANCE: MP08‐12 (2017) (0)
- Abstract LB-115: TPRKB dependency in p53-deficient cancers (2017) (0)
- Abstract 712: Antitumor activity of SPINK1 monoclonal antibody in a subset ofSPINK1positiveETS-negative prostate cancer (2010) (0)
- 2158 COMBINING TMPRSS2:ERG AND PCA3 IN POST-DRE URINE WITH SERUM PSA TO IDENTIFY PROSTATE BIOPSY CANDIDATES: DEVELOPMENT AND VERIFICATION OF A CLINICALLY PRACTICAL ALGORITHM (2010) (0)
- CLINICOPATHOLOGIC CHARACTERISTICS OF PATIENTS WITH VERY LOW‐RISK (PI‐RADS 1 OR 2) LESIONS BY MULTIPARAMETRIC PROSTATE MAGNETIC RESONANCE IMAGING: MP38‐17 (2017) (0)
- Abstract A1-43: Targeted amplicon-based next-generation sequencing of routine solid tumor specimens to detect clinically relevant somatic alterations (2015) (0)
- Prostatic Adenocarcinoma With Hormone Exposure Related Changes in a Patient With Hepatic Cirrhosis – Value of Autopsy in a Case Report (2016) (0)
- SAT-549 Identification of Somatic Mutations in CLCN2 as a Cause of Aldosterone-Producing Adenomas (2020) (0)
- Abstract 1860: DNA-PK-mediated transcriptional regulation drives tumor progression and metastasis (2015) (0)
- Autophagy inhibition (AI) as a novel treatment strategy in bladder cancer (BC). (2016) (0)
- Characterization of urothelial carcinoma with seminal vesicle involvement in locally advanced bladder cancer. (2016) (0)
- PD08-07 MOLECULAR PROGRESSION OF GLEASON 6 PROSTATE CANCER: TRACKING OF SPECIFIC CLONES BY IMAGE-GUIDED BIOPSY (2016) (0)
- Association of gene expression module biomarkers with clinical and therapeutic endpoints and their use with a universal companion diagnostic assay. (2011) (0)
- Label free aggressive prostate cancer identification with ultraviolet photoacoustic spectral analysis (Conference Presentation) (2017) (0)
- Comprehensive molecular dissection of multi-focal prostate cancer and concomitant lymph node metastasis: Implications for tissue based prognostic biomarkers (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Scott Arthur Tomlins?
Scott Arthur Tomlins is affiliated with the following schools:
